ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast

[News]

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.

More... (http://www.news-medical.net/news/20120604/ImmunoGen-reports-data-from-T-DM1-Phase-III-trial-on-HER2-positive-metastatic-breast-cancer.aspx)